PETRI DISH PERSPECTIVES

Manead Khin
  • 0.0 (0)
  • Life Sciences

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. 6d ago

    Episode 60: Hims & Hers

    Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscription medicine, and aggressive branding to reach millions of patients. We explore the company's founding story, rapid growth, SPAC-era public debut, expansion into mental health, dermatology, weight loss, and primary care, as well as the controversies surrounding compounded GLP-1 medications, regulatory scrutiny, and the broader debate around the future of telemedicine. From Silicon Valley startup to healthcare disruptor, Hims & Hers offers a fascinating case study in consumerization, accessibility, and the changing relationship between patients and providers. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #HimsAndHers #Telehealth #DigitalHealth #HealthcareInnovation #GLP1 #WeightLossDrugs #Biotech #HealthcareBusiness #StartupStories #PublicMarkets #HealthcareTechnology #DirectToConsumer #Pharma #HealthTech #BusinessPodcast #AndrewDudum #Medicine #HealthcareDisruption #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    26 min

  2. Jun 11

    Episode 59: Illumina

    Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale genetic studies. You'll hear how the company built an empire around the idea that reading DNA would become as essential to medicine as blood tests and imaging scans. We also unpack the major milestones that shaped Illumina's rise: the acquisition of Solexa, the launch of revolutionary sequencing platforms, the race to the "$1,000 genome," and the company's ambitious vision for detecting cancer through blood tests. Along the way, we'll examine the controversial Grail acquisition, regulatory battles with the European Union, leadership shakeups, and the strategic decisions that defined one of biotech's most influential companies. From the Human Genome Project to multi-billion-dollar cancer screening ambitions, this is the story of the company that made genomics mainstream. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Illumina #Genomics #DNASequencing #HumanGenomeProject #Grail #CancerDetection #LiquidBiopsy #Biotech #Biotechnology #PrecisionMedicine #GeneticTesting #NextGenerationSequencing #NGS #LifeSciences #HealthcareInnovation #MolecularBiology #CancerResearch #BioTechPodcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    23 min

  3. Jun 4

    Episode 58: UnitedHealthcare

    Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hundreds of billions of dollars, UnitedHealthcare has fundamentally transformed how healthcare is financed, delivered, and managed in the United States. We explore the company's founding story, the leadership of industry-defining executives, the creation of Optum, and the acquisition strategy that turned UnitedHealth into far more than an insurance company. We also unpack the controversies surrounding prior authorizations, claim denials, Medicare Advantage investigations, antitrust concerns, and the growing public frustration with the American healthcare system. Finally, we examine one of the most shocking moments in modern corporate history: the assassination of CEO Brian Thompson in 2024, the national conversation it sparked, and what it revealed about the growing tension between healthcare corporations and the patients they serve. This is a story about scale, innovation, power, controversy, and the future of healthcare itself. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #UnitedHealthcare #UnitedHealthGroup #Optum #Healthcare #HealthInsurance #MedicareAdvantage #HealthcareInnovation #HealthcareBusiness #Biotech #Pharma #HealthTech #BrianThompson #CorporateStrategy #PetriDishPerspectives #HealthcarePolicy #DigitalHealth #ValueBasedCare #ManagedCare #HealthcareEconomics #BusinessPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    24 min

  4. Jun 1

    May 2026: Biotech & Pharma NEWS Roundup

    Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure the next generation of oncology, metabolic, and infectious disease assets. From high-stakes acquisitions aimed at building comprehensive "acute care" architectures to massive investments in generative AI-driven discovery engines, the industry has clearly shifted toward a model of integrated precision, prioritizing both the speed of research and the consolidation of complex manufacturing infrastructure. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    11 min

  5. May 28

    Episode 57: 23andMe

    Send us Fan Mail This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes. From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe built a direct-to-consumer model that reshaped public engagement with DNA. We break down the science behind SNP genotyping, the shift from ancestry testing to drug discovery partnerships with pharma giants like GSK, and the promise and limits of consumer-driven precision medicine. We also dive into the SPAC-era hype cycle, regulatory and FDA battles, privacy controversies around genetic data ownership, and the deeper ethical question at the heart of the company: who actually owns your biology once it’s been digitized? This is a story about genetics, identity, data, and the uneasy intersection of science and consumer tech. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #23andMe #Genetics #Biotech #DNA #Genomics #PrecisionMedicine #HealthcareInnovation #BioTech #Pharma #DataPrivacy #ConsumerGenomics #SPAC #DrugDiscovery #SciencePodcast #PetriDishPerspectives #Ancestry #DigitalHealth Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    26 min

  6. May 21

    Episode 56: Thermo Fisher

    Send us Fan Mail This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufacturing, and the “picks-and-shovels” strategy behind biotech’s biggest breakthroughs. We also unpack the company’s role during COVID-19, its expansion into CDMO services, and why some of the most powerful companies in healthcare are often the ones nobody talks about. This is the story of the invisible engine behind modern biology and the company behind the companies. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #ThermoFisher #Biotech #LifeSciences #Biotechnology #Pharma #DrugDevelopment #Genomics #Diagnostics #CDMO #HealthcareInnovation #PrecisionMedicine #Science #Biopharma #PetriDishPerspectives #LaboratoryScience #SyntheticBiology #ThermoFisherScientific Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    23 min

  7. May 14

    Episode 55: Alnylam

    Send us Fan Mail From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine. We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine. This is the story of persistence, platform biology, and the rise of RNA therapeutics. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    24 min

  8. May 7

    Episode 54: All about 340B

    Send us Fan Mail In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients. But over time, it has evolved into something much bigger. We unpack how the program actually works, why it’s become a financial cornerstone for many hospital systems, and the growing tension with pharmaceutical companies like Pfizer and Johnson & Johnson. From contract pharmacy battles to questions around transparency and patient benefit, the 340B ecosystem sits at the center of one of the most complex, and controversial, debates in healthcare economics. Because 340B isn’t just about drug discounts. It’s about who captures value in the healthcare system and who it’s really meant to serve. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #340B #HealthcarePolicy #Pharma #DrugPricing #HealthEconomics #Biotech #HealthcareInnovation #PetriDishPerspectives #USHealthcare #PolicyExplained Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

    17 min
See All (67)

About

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

Information

  • Creator
    Manead Khin
  • Years Active
    2025 - 2026
  • Episodes
    67
  • Rating
    Explicit
  • Copyright
    © 2026 PETRI DISH PERSPECTIVES
  • Show Website
    PETRI DISH PERSPECTIVES